Cart
sales@molnova.com
Firategrast
CAS No. 402567-16-2
Firategrast( —— )
Catalog No. M37947 CAS No. 402567-16-2
Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist that reduces the transport of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 5MG | 85 | In Stock |
|
| 10MG | 136 | In Stock |
|
| 25MG | 282 | In Stock |
|
| 50MG | 454 | In Stock |
|
| 100MG | 732 | In Stock |
|
| 200MG | 995 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFirategrast
-
NoteResearch use only, not for human use.
-
Brief DescriptionFirategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist that reduces the transport of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.
-
DescriptionFirategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.
-
In VitroFirategrast (0.1-10 μM; 1 hour) significantly reduces chronic lymphocytic leukemia (CLL) cells adhesion. Firategrast is a potent Integrin α4β1 (VLA-4) antagonist (IC50=198 nM) at inhibiting the binding of soluble VCAM/Fc chimeric protein (sVCAM-1) to G2 acute lymphoblastic leukemia (ALL) cells. VLA-4 is composed of CD49d (α4) and CD29 (β1).
-
In VivoFirategrast (30?mg/kg/day in drinking water; starting 2 or 7 days post transplantation to 21 days) shows an overall reduction of leukemic cells in the spleen. Animal Model:Female Wild-type C57BL/6J mice (8-12 weeks) with primary TCL1-tg splenocytes Dosage:30?mg/kg Administration:Drinking water; daily; starting 2 or 7 days post transplantation to 21 days Result:Showed an overall reduction of leukemic cells in the spleen, accompanied by significant spleen weight reduction.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number402567-16-2
-
Formula Weight499.5
-
Molecular FormulaC27H27F2NO6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (200.20 mM; ) Ethanol : ≥ 50 mg/mL (100.10 mM)
-
SMILESCCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Moses O. Evbuomwan, et al. Generation and Characterization of Novel VLA-4 Inhibitors for Stem Cell Mobilization in Combination with a CXCR2 Agonist. Blood (2017) 130 (Supplement 1): 3197.
molnova catalog
related products
-
Gly-Arg-Gly-Asp-Ser
Gly-Arg-Gly-Asp-Ser (GRGDS) GRGDS is a cell binding protein domain derived from the cell-binding region of fibronectin.
-
Cyclo(RADfK)
Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.Cyclo(RADfK) is a negative control for the cyclo (-RGDfK-), the RGD peptide.
-
Valategrast
Valategrast is a potent, α4β1 (VLA-4) and α4β7 dual antagonist.
